Tim Wilsdon recently presented at an education forum at ISPOR Latin America, talking about the challenges that gene therapy poses for value assessment and considerations for the future.
For more information about the conference, click here.
From ASP to MFP: The looming disruption of the medical benefit
Key recent developments in the program include: The first two years of the MDPNP only covered retail-dispensed therapies but starting in this selection...